Harbour BioMed Raises $85 Million in Series B Financing to Accelerate Its Innovative Pipeline SHANGHAI & ROTTERDAM, The Netherlands & CAMBRIDGE, Mass., August 27, 2018-- Harbour BioMed announced today that it has completed a Series B round financing of $85 million to accelerate the growth of its innovative therapeutic pipeline, including both clinical and discovery stage programs. GIC Private Limited, Singapore's sovereign wealth fund, led the financing round, with participation from new investors, including China Life Private Equity Investment Company and Vertex Ventures, and Series A investors AdvanTech and Legend Capital.